A synthetic research combination of a GHRH analog and a ghrelin receptor (GHS-R1a) agonist. Utilized in laboratory models to investigate dual-receptor signaling, pituitary responsiveness, and growth hormone pathway modulation. For research use only. Not for human consumption.
The CJC-1295 (No DAC) and Hexarelin blend combines two synthetic research peptides frequently evaluated in experimental models of growth hormone regulation and pituitary signaling. CJC-1295, also known as Mod GRF 1–29, is a truncated growth hormone–releasing hormone analog that binds to the GHRH receptor and activates intracellular cAMP-dependent signaling pathways associated with somatotropic hormone release.
Hexarelin is a ghrelin receptor (GHS-R1a) agonist studied for its ability to influence calcium-dependent signaling cascades through phospholipase C activation. In laboratory research, Hexarelin is commonly used to examine pituitary responsiveness, receptor-mediated signaling dynamics, and peptide–receptor interactions.
When assessed together, this peptide combination serves as a research model for investigating coordinated GHRH and ghrelin receptor activity, peptide stability, and mechanisms involved in growth hormone pathway modulation under controlled experimental conditions.
For research use only. Not for human consumption.
References
Bowers CY, et al. Endocrinology. 1990;126(2):1165–1171.
Ghigo E, et al. European Journal of Endocrinology. 2001;145(1):1–10.
Teichman SL, et al. Journal of Clinical Endocrinology & Metabolism. 2006;91(2):479–487.